AIGEN Sciences Raises 12B KRW in Funding
AIGEN Sciences, a Seoul, South Korea-based AI-driven new drug development company, has raised 12 billion KRW in funding.
AIGEN Sciences, a Seoul, South Korea-based AI-driven new drug development company, has raised 12 billion KRW in funding.
Investors
Existing investors Partners Investment, Quad Asset Management, and Medytox Venture Investment, along with new investors Premier Partners, K2 Investment, and Scaleup Partners, participated in the round.
AIGEN Sciences Use of Funds
The company will use the funding to enhance its drug development capabilities and accelerate growth.
About AIGEN Sciences
Founded in April 2021, AIGEN Sciences is an AI drug discovery platform that provides drug research and development services. It utilizes its proprietary AI drug development platform to create small-molecule synthetic drugs targeting intractable diseases with high unmet medical needs. Its robust pipeline includes multiple lead substance optimizations and preclinical candidates. The company aims to advance state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient processes.
Funding Details
Company: AIGEN Sciences, Inc.
Raised: 12.0B KRW
Round: Unknown
Funding Date: October 2024
Investors: Partners Investment, Quad Asset Management, Medytox Venture Investment, Premier Partners, K2 Investment, Scaleup Partners
Company Website: https://www.aigensciences.com/
Software Category: AI Drug Development
